pasireotide 40 MG Injection
Semantic Scholar uses AI to extract papers important to this topic.
Acromegaly is a rare disease due to chronic excess growth hormone (GH) and IGF-1. Aryl hydrocarbon receptor interacting protein… Expand PurposeMedullary thyroid cancer (MTC) is a neuroendocrine tumour of the thyroid C cells. Pasireotide, a multi-receptor targeted… Expand Background Long‐term medical management of hypersomatotropism (HS) in cats has proved unrewarding. Pasireotide, a novel… Expand Pasireotide (Signifor®) long-acting release (LAR) is a next-generation somatostatin receptor ligand (SRL) approved for treatment… Expand Abstract Background: Acromegaly is a rare disorder characterized by the over-production of growth hormone (GH). Patients often… Expand Objective: A subset of meningiomas recur after surgery and radiation therapy, but no medical therapy for recurrent meningioma has… Expand PurposePasireotide LAR (SOM230 LAR) is a cyclohexapeptide engineered to bind to multiple somatostatin receptor subtypes to mimic… Expand PurposeA large, randomized, double-blind, Phase III core study demonstrated that pasireotide LAR was significantly superior to… Expand 241 Background: Pasireotide LAR is a novel somatostatin analog (SSA) with avid binding to somatostatin receptor subtypes (SSTR) 1… Expand 2040 Background: Patients with recurrent or progressive meningiomas who have exhausted surgical and radiation options have… Expand